ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,729Medicare Part D Prescriptions Filled, Including Refills

Rank: 160 out of 2456

$602K Total Retail Price of All Prescriptions

Rank: 156 out of 2456

496 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
31% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Massachusetts
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 496 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

6% of this provider’s 496 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 9,988 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$56 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Massachusetts
SIMVASTATIN 469 436 1 2
LISINOPRIL 445 401 2 1
OMEPRAZOLE 432 396 3 3
LEVOTHYROXINE SODIUM 417 385 4 4
FUROSEMIDE 378 378 5 8
HYDROCHLOROTHIAZIDE 369 338 6 7
WARFARIN SODIUM 295 289 7 9
ATENOLOL 283 239 8 6
METOPROLOL TARTRATE 274 270 9 10
CITALOPRAM HBR 250 235 10 14
AMLODIPINE BESYLATE 230 224 11 5
ATORVASTATIN CALCIUM 212 205 12 12
METFORMIN HCL 211 202 13 11
ALENDRONATE SODIUM 202 189 14 19
SERTRALINE HCL 176 176 15 21
TAMSULOSIN HCL 154 145 16 32
ALLOPURINOL 147 133 17 27
PREDNISONE 146 144 18 39
TRAZODONE HCL 133 128 19 17
MIRTAZAPINE 133 133 19 29
METOPROLOL SUCCINATE 113 113 21 13
DONEPEZIL HCL 111 106 22 23
POTASSIUM CHLORIDE 110 98 23 33
FINASTERIDE 103 103 24 66
NAMENDA 99 99 25 42
TRAMADOL HCL 99 99 25 24
SPIRIVA 83 76 27 43
DIGOXIN 83 80 27 49
PAROXETINE HCL 81 64 29 56
LOSARTAN POTASSIUM 77 77 30 18
CLOPIDOGREL 75 62 31 55
LACTULOSE 73 73 32 88
ADVAIR DISKUS 70 69 33 36
CELEBREX 70 58 33 127
GABAPENTIN 69 46 35 16
FLUTICASONE PROPIONATE 68 53 36 30
LANTUS 68 68 36 44
GLYBURIDE 66 58 R 38 40
PANTOPRAZOLE SODIUM 64 52 39 37
DIOVAN 63 63 40 26
LIDODERM 60 60 41 58
TERAZOSIN HCL 58 58 42 76
RISPERIDONE 56 56 43 50
CARVEDILOL 53 43 44 54
HYDROCODONE-ACETAMINOPHEN 52 47 S3 45 20
COLCRYS 51 51 46 171
PROAIR HFA 50 50 47 22
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 20, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.